UniProt P25451
Proteasome subunit beta type-3 (P25451)
Proteasome subunit beta type-3 (UniProt P25451), EC 3.4.25.1: 544 experimental structures on GenesisL1, 30 ligands bound, 122 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- P25451
- Protein
- Proteasome subunit beta type-3
- EC
- 3.4.25.1
- Experimental structures
- 544
- Predicted models
- 0
- Ligands
- 30
- Pockets
- 122 · 25 records with a druggable one
Structures
544 records of P25451 in the MolNFT archive: 544 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1FNT | Crystal structure of the 20S proteasome from yeast in complex with the proteasome activator PA26… | x-ray diffraction | J, X | — | — |
| 1FNT | Crystal structure of the 20S proteasome from yeast in complex with the proteasome activator PA26… | x-ray diffraction | J, X | — | — |
| 1G0U | A gated channel into the proteasome core particle | x-ray diffraction | I, W | — | — |
| 1G0U | A gated channel into the proteasome core particle | x-ray diffraction | I, W | — | — |
| 1G65 | Crystal structure of epoxomicin:20s proteasome reveals a molecular basis for selectivity of… | x-ray diffraction | I, W | — | — |
| 1G65 | Crystal structure of EPOXOMICIN:20S proteasome reveals a molecular basis for selectivity of… | x-ray diffraction | I, W | — | — |
| 1JD2 | Crystal Structure of the yeast 20S Proteasome:TMC-95A complex: A non-covalent Proteasome Inhibitor | x-ray diffraction | I, P | — | — |
| 1JD2 | Crystal structure of the yeast 20S PROTEASOME:TMC-95A complex: a non- covalent proteasome inhibitor | x-ray diffraction | I, P | — | — |
| 1RYP | Crystal structure of the 20S proteasome from yeast at 2.4 ångströms resolution | x-ray diffraction | J, X | — | — |
| 1RYP | Crystal structure of the 20S proteasome from yeast at 2.4 ångströms resolution | x-ray diffraction | J, X | — | — |
| 1Z7Q | Crystal structure of the 20s proteasome from yeast in complex with the proteasome activator PA26… | x-ray diffraction | J, X | — | — |
| 1Z7Q | Crystal structure of the 20S proteasome from yeast in complex with the proteasome activator PA26… | x-ray diffraction | J, X | — | — |
| 2F16 | Crystal structure of the yeast 20S proteasome in complex with bortezomib | x-ray diffraction | I, W | — | — |
| 2F16 | Crystal structure of the yeast 20S proteasome in complex with bortezomib | x-ray diffraction | I, W | — | — |
| 2FAK | Crystal structure of Salinosporamide A in complex with the yeast 20S proteasome | x-ray diffraction | I, W | — | — |
| 2FAK | Crystal structure of salinosporamide a in complex with the yeast 20S proteasome | x-ray diffraction | I, W | — | — |
| 2GPL | TMC-95 based biphenyl-ether macrocycles: specific proteasome inhibitors | x-ray diffraction | I, W | — | — |
| 2GPL | Tmc-95 based biphenyl-ether macrocycles: specific proteasome inhibitors | x-ray diffraction | I, W | — | — |
| 2ZCY | yeast 20S proteasome:syringolin A-complex | x-ray diffraction | I, W | — | — |
| 2ZCY | Yeast 20S PROTEASOME:SYRINGOLIN a-complex | x-ray diffraction | I, W | — | — |
| 3BDM | yeast 20S proteasome:glidobactin A-complex | x-ray diffraction | I, W | — | — |
| 3BDM | Yeast 20S PROTEASOME:GLIDOBACTIN a-complex | x-ray diffraction | I, W | — | — |
| 3D29 | Proteasome inhibition by fellutamide B | x-ray diffraction | I, W | — | — |
| 3DY3 | Crystal structure of yeast 20S proteasome in complex with the epimer form of spirolactacystin | x-ray diffraction | I, W | — | — |
| 3DY3 | Crystal structure of yeast 20S proteasome in complex with the epimer form of spirolactacystin | x-ray diffraction | I, W | — | — |
| 3DY4 | Crystal structure of yeast 20S proteasome in complex with spirolactacystin | x-ray diffraction | I, W | — | — |
| 3DY4 | Crystal structure of yeast 20S proteasome in complex with spirolactacystin | x-ray diffraction | I, W | — | — |
| 3E47 | Crystal Structure of the Yeast 20S Proteasome in Complex with Homobelactosin C | x-ray diffraction | I, W | — | — |
| 3E47 | Crystal structure of the yeast 20S proteasome in complex with homobelactosin C | x-ray diffraction | I, W | — | — |
| 3GPJ | Crystal structure of the yeast 20S proteasome in complex with syringolin B | x-ray diffraction | I, W | — | — |
| 3GPJ | Crystal structure of the yeast 20S proteasome in complex with syringolin B | x-ray diffraction | I, W | — | — |
| 3GPT | Crystal structure of the yeast 20S proteasome in complex with Salinosporamide derivatives: slow… | x-ray diffraction | I, W | — | — |
| 3GPT | Crystal structure of the yeast 20S proteasome in complex with salinosporamide derivatives: slow… | x-ray diffraction | I, W | — | — |
| 3GPW | Crystal structure of the yeast 20S proteasome in complex with Salinosporamide derivatives… | x-ray diffraction | I, W | — | — |
| 3GPW | Crystal structure of the yeast 20S proteasome in complex with salinosporamide derivatives… | x-ray diffraction | I, W | — | — |
| 3HYE | Crystal structure of 20S proteasome in complex with hydroxylated salinosporamide | x-ray diffraction | I, W | — | — |
| 3HYE | Crystal structure of 20S proteasome in complex with hydroxylated salinosporamide | x-ray diffraction | I, W | — | — |
| 3JCO | Structure of yeast 26S proteasome in M1 state derived from Titan dataset | electron microscopy | 5, j | — | — |
| 3JCP | Structure of yeast 26S proteasome in M2 state derived from Titan dataset | electron microscopy | 5, j | — | — |
| 3MG0 | Structure of yeast 20S proteasome with bortezomib | x-ray diffraction | I, W | — | — |
| 3MG0 | Structure of yeast 20S proteasome with bortezomib | x-ray diffraction | I, W | — | — |
| 3MG4 | Structure of yeast 20S proteasome with Compound 1 | x-ray diffraction | I, W | — | — |
| 3MG4 | Structure of yeast 20S proteasome with compound 1 | x-ray diffraction | I, W | — | — |
| 3MG6 | Structure of yeast 20S open-gate proteasome with Compound 6 | x-ray diffraction | I, W | — | — |
| 3MG6 | Structure of yeast 20S open-gate proteasome with compound 6 | x-ray diffraction | I, W | — | — |
| 3MG7 | Structure of yeast 20S open-gate proteasome with Compound 8 | x-ray diffraction | I, W | — | — |
| 3MG7 | Structure of yeast 20S open-gate proteasome with compound 8 | x-ray diffraction | I, W | — | — |
| 3MG8 | Structure of yeast 20S open-gate proteasome with Compound 16 | x-ray diffraction | I, W | — | — |
| 3MG8 | Structure of yeast 20S open-gate proteasome with compound 16 | x-ray diffraction | I, W | — | — |
| 3NZJ | Crystal structure of yeast 20S proteasome in complex with ligand 2a | x-ray diffraction | I, W | — | — |
| 3NZJ | Crystal structure of yeast 20S proteasome in complex with ligand 2A | x-ray diffraction | I, W | — | — |
| 3NZW | Crystal structure of the yeast 20S proteasome in complex with 2b | x-ray diffraction | I, W | — | — |
| 3NZW | Crystal structure of the yeast 20S proteasome in complex with 2B | x-ray diffraction | I, W | — | — |
| 3NZX | Crystal structure of the yeast 20S proteasome in complex with ligand 2c | x-ray diffraction | I, W | — | — |
| 3NZX | Crystal structure of the yeast 20S proteasome in complex with ligand 2C | x-ray diffraction | I, W | — | — |
| 3OEU | Structure of yeast 20S open-gate proteasome with Compound 24 | x-ray diffraction | I, W | — | — |
| 3OEU | Structure of yeast 20S open-gate proteasome with compound 24 | x-ray diffraction | I, W | — | — |
| 3OEV | Structure of yeast 20S open-gate proteasome with Compound 25 | x-ray diffraction | I, W | — | — |
| 3OEV | Structure of yeast 20S open-gate proteasome with compound 25 | x-ray diffraction | I, W | — | — |
| 3OKJ | Alpha-keto-aldehyde binding mechanism reveals a novel lead structure motif for proteasome inhibition | x-ray diffraction | I, W | — | — |
484 records more on the page itself.
Ligands
- MG · Magnesium ion · in 156 records
- 3BV · N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-[(2R,3S,4S)-1,3-dihydroxy-2,6-dimethylheptan-4-yl]-L-phenylalaninamide · in 10 records
- BO2 · N-[(1R)-1-(dihydroxyboryl)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide · in 9 records
- 04C · 1,2,4-trideoxy-4-methyl-2-{[N-(morpholin-4-ylacetyl)-L-alanyl-O-methyl-L-tyrosyl]amino}-1-phenyl-D-xylitol · in 7 records
- GQQ · ~{N}-[(2~{S})-1-[[(2~{S})-1-[[(2~{S})-1-[4-(aminomethyl)phenyl]-4-methylsulfonyl-butan-2-yl]amino]-4-methyl-1-oxidanylidene-pentan-2-yl]amino]-4-methyl-1-oxidanylidene-pentan-2-yl]pyrazine-2-carboxamide · in 6 records
- GRT · (2~{S})-~{N}-[2-[[(2~{S})-1-[4-(aminomethyl)phenyl]-4-methylsulfonyl-butan-2-yl]amino]-2-oxidanylidene-ethyl]-2-[[(2~{S})-2-azido-3-phenyl-propanoyl]amino]-4-methyl-pentanamide · in 6 records
- GTW · ~{N}-[(2~{S})-1-[[(2~{S})-1-[[(2~{S})-1-[4-(aminomethyl)phenyl]-4-methylsulfonyl-butan-2-yl]amino]-3-cyclohexyl-1-oxidanylidene-propan-2-yl]amino]-4-methyl-1-oxidanylidene-pentan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide · in 6 records
- GQH · (2~{S})-~{N}-[(2~{S})-1-[[(2~{S})-1-[4-(aminomethyl) phenyl]-4-methylsulfonyl-butan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-2-[[(2~{S})-2-azido-3-phenyl-propanoyl]amino]-4-methyl-pentanamide · in 5 records
- GQK · (2~{S})-3-(4-methoxyphenyl)-~{N}-[(2~{S},3~{R})-4-methyl-3,4-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{S})-2-(2-morpholin-4-ylethanoylamino) propanoyl]amino]propanamide · in 5 records
- GRW · (2~{S})-~{N}-[(2~{S},3~{R})-1-[[(2~{S})-1-[4-(aminomethyl)phenyl]-4-methylsulfonyl-butan-2-yl]amino]-3-oxidanyl-1-oxidanylidene-butan-2-yl]-2-[[(2~{R})-2-azido-3-phenyl-propanoyl]amino]-4-methyl-pentanamide · in 5 records
- GT5 · ~{N}-[(2~{S})-1-[[(2~{S})-1-[[(2~{S})-1-[4-(aminomethyl)phenyl]-4-methylsulfonyl-butan-2-yl]amino]-3-methoxy-1-oxidanylidene-propan-2-yl]amino]-4-methyl-1-oxidanylidene-pentan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide · in 5 records
- GT8 · (2~{S})-~{N}-[(3~{S},4~{R})-1-cyclohexyl-5-methyl-4,5-bis(oxidanyl)hexan-3-yl]-3-(4-methoxyphenyl)-2-[[(2~{S})-2-(2-morpholin-4-ylethanoylamino) propanoyl]amino]propanamide · in 5 records
- 79L · (2~{S})-3-(4-methoxyphenyl)-~{N}-[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{R})-2-(2-morpholin-4-ylethanoylamino) propanoyl]amino]propanamide · in 4 records
- 79P · (2~{S})-3-(1~{H}-indol-3-yl)-~{N}-[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{R})-2-(2-morpholin-4-ylethanoylamino) propanoyl]amino]propanamide · in 4 records
- GQT · (2~{S})-~{N}-[(2~{S})-1-[[(2~{S})-1-[4-(aminomethyl) phenyl]-4-methylsulfonyl-butan-2-yl]amino]-3-oxidanyl-1-oxidanylidene-propan-2-yl]-2-[[(2~{S})-2-azido-3-phenyl-propanoyl]amino]-4-methyl-pentanamide · in 4 records
- 6N5 · ~{N}-[(2~{S})-1-[[(2~{S})-3-(4-methoxyphenyl)-1-[[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]amino]-1-oxidanylidene-propan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-1-methyl-5~{H}-indene-2-carboxamide · in 3 records
- EQE · (2~{S},3~{R})-4-[[(2~{S})-3-methyl-1-[[(2~{S})-3-methyl-1-oxidanylidene-1-phenylmethoxy-butan-2-yl]amino]-1-oxidanylidene-butan-2-yl]amino]-3-oxidanyl-4-oxidanylidene-2-propan-2-yl-butanoic acid · in 2 records
- GWK · (2~{S})-3-(4-methoxyphenyl)-~{N}-[(2~{S},3~{R})-4-methyl-1-(4-methylcyclohexyl)-3,4-bis(oxidanyl)pentan-2-yl]-2-[[(2~{S})-2-(2-morpholin-4-ylethanoylamino) propanoyl]amino]propanamide · in 2 records
- GWT · (2~{S})-~{N}-[(2~{S},3~{R})-1-(4-cyclohexylcyclohexyl)-4-methyl-3,4-bis(oxidanyl)pentan-2-yl]-3-(4-methoxyphenyl)-2-[[(2~{S})-2-(2-morpholin-4-ium-4-ylethanoylamino)propanoyl]amino]propanamide · in 2 records
- GWZ · (2~{S})-~{N}-[(2~{S})-1-[[(3~{R},4~{S})-2,6-dimethyl-2, 3-bis(oxidanyl)heptan-4-yl]amino]-1-oxidanylidene-3-phenyl-propan-2-yl]-4-methyl-2-[[(2~{S})-2-(2-morpholin-4-ylethanoylamino)-4-phenyl-butanoyl]amino]pentanamide · in 2 records
- QOE · (2~{S},3~{R})-~{N}-[(5~{S},8~{S},10~{S})-5-methyl-10-oxidanyl-2,7-bis(oxidanylidene)-1,6-diazacyclododec-8-yl]-3-oxidanyl-2-(3-phenylpropanoylamino)butanamide · in 2 records
- 5BY · {2-[2-(2-{4-[(1E)-4-{[(2S)-1-{[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]amino}-1-oxo-3-phenylpropan-2-yl]amino}-4-oxobut-1-en-1-yl]-1H-1,2,3-triazol-1-yl}ethoxy)ethoxy]ethoxy}acetic acid · in 1 record
- 5BZ · [(1~{R})-1-[[(2~{S})-2-(hex-5-ynoylamino)-3-phenyl-propanoyl]amino]-3-methyl-butyl]boronic acid · in 1 record
- 6KG · Nalpha-[(2S)-2-{[(2S)-2-azido-3-phenylpropanoyl]amino}-4-cyclohexylbutanoyl]-N-[(2R,3S,4S)-1,3-dihydroxy-2,6-dimethylheptan-4-yl]-L-phenylalaninamide · in 1 record
- GVW · (2~{S})-~{N}-[(2~{S},3~{R})-1-[(4~{A}~{S},8~{A}~{S})-1, 2,3,4,4~{A},5,6,7,8,8~{A}-decahydronaphthalen-2-yl]-4-methyl-3,4-bis(oxidanyl)pentan-2-yl]-3-(4-methoxyphenyl)-2-[[(2~{S})-2-(2-morpholin-4-ylethanoylamino)propanoyl]amino]propanamide · in 1 record
- GVZ · (2~{S})-~{N}-[(2~{S},3~{R})-1-[(1~{S},4~{A}~{S}, 8~{A}~{R})-1,2,3,4,4~{A},5,6,7,8,8~{A}-decahydronaphthalen-1-yl]-4-methyl-3,4-bis(oxidanyl) pentan-2-yl]-3-(4-methoxyphenyl)-2-[[(2~{S})-2-(2-morpholin-4-ylethanoylamino) propanoyl]amino]propanamide · in 1 record
- GW2 · (2~{S})-~{N}-[(2~{S},3~{S},4~{R})-1-[(1~{S},4~{A}~{S}, 8~{A}~{R})-1,2,3,4,4~{A},5,6,7,8,8~{A}-decahydronaphthalen-1-yl]-4-methyl-3,5-bis(oxidanyl) pentan-2-yl]-3-(4-methoxyphenyl)-2-[[(2~{S})-2-(2-morpholin-4-ylethanoylamino) propanoyl]amino]propanamide · in 1 record
- QOB · ~{N}-[(2~{S},3~{R})-1-[[(5~{S},8~{S},10~{S})-5-methyl-10-oxidanyl-2,7-bis(oxidanylidene)-1,6-diazacyclododec-8-yl]amino]-3-oxidanyl-1-oxidanylidene-butan-2-yl]-5-phenyl-pentanamide · in 1 record
- QOH · 11-methyl-~{N}-[(2~{S},3~{R})-1-[[(5~{S},8~{S},10~{S})-5-methyl-10-oxidanyl-2,7-bis(oxidanylidene)-1,6-diazacyclododec-8-yl]amino]-3-oxidanyl-1-oxidanylidene-butan-2-yl]dodecanamide · in 1 record
- SRG · (2S)-2-[[(2S)-1-[[(5S,8S,9E)-2,7-dioxo-5-propan-2-yl-1,6-diazacyclododeca-3,9-dien-8-yl]amino]-3-methyl-1-oxo-butan-2-yl]carbamoylamino]-3-methyl-butanoic acid · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.